MENU
FOCL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

FOCL stock forecast, quote, news & analysis

Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 03, 2026

FocalTherics (FOCL) Stock Analysis: Robotic HIFU Expansion Sets the Stage for Q3 Results

Key Takeaways

  • FocalTherics (FOCL), formerly EDAP TMS, traded near $4.32, a modest gain of roughly 2.9% over the trailing 30 days following its rebrand to a pure-play robotic focal therapy company.
  • The stock has consolidated in a tight range between roughly $4.00 and $4.75, reflecting balanced investor sentiment ahead of a key earnings release.
  • Second-quarter 2026 HIFU revenue rose 39% year-over-year to $13.2 million, with gross margin improving to 55.6%.
  • Management reiterated full-year 2026 HIFU revenue guidance of $50 million to $54 million, implying 34% to 45% growth.
  • Third-quarter 2026 financial results are scheduled for release after the market close on November 5, 2026, making earnings the primary near-term catalyst.
  • Operating losses and funding considerations remain the central risks, even as the company targets a 40% revenue CAGR through 2028.
  • For deeper detail on valuation, results, and projections, explore FocalTherics Price Targets, Earnings, and Forecast pages.
  • To see how automated strategies are positioned across the market, explore Trending AI Robots.

Current Market Snapshot

FocalTherics shares have traded with limited volatility over the past month, holding near $4.32 after closing at roughly $4.20 approximately 30 days earlier. The roughly 2.9% advance reflects a period of consolidation rather than a sharp directional move, with the stock continuing to fluctuate in a band between about $4.00 and $4.75 on comparatively modest daily volume. As a small-cap medical technology name, FOCL is sensitive to clinical data releases, quarterly results, and shifts in healthcare-sector sentiment, factors that have kept traders attentive ahead of the company's upcoming earnings report.

FocalTherics (FOCL) Business Overview and Competitive Position

FocalTherics, whose legal name remains EDAP TMS S.A., develops, manufactures, and markets minimally invasive medical devices powered by proprietary focused ultrasound technology. The company's flagship platform, Focal One® Robotic HIFU, combines advanced imaging, real-time treatment planning, and robotic precision to deliver personalized focal therapy for localized prostate cancer while aiming to preserve urinary and sexual function. In mid-2026, the company adopted the FocalTherics identity and moved its Nasdaq listing from EDAP to FOCL, classifying its legacy lithotripsy (ESWL) and distribution segments as discontinued operations to focus exclusively on high-growth robotic focal therapy. The platform has gained adoption across major academic and community institutions, supported by growing clinical evidence, expanding reimbursement, and early efforts into additional indications.

Recent Developments Driving FOCL

Several verified developments have shaped investor sentiment over recent months. The corporate rebrand and ticker change to FOCL, effective June 1, 2026, sharpened the company's identity around its Focal One platform. In August, FocalTherics reported second-quarter results showing HIFU revenue of $13.2 million, a 39% year-over-year increase, alongside a gross margin of 55.6% and reaffirmed 2026 guidance of $50 million to $54 million. The company also completed a $40 million equity financing to fund commercial expansion, research, and new indications. On October 22, 2026, FocalTherics announced it would report third-quarter results on November 5, 2026, focusing investor attention on the near-term earnings print. Earlier catalysts, including an FDA 510(k) clearance for the latest Focal One evolution and a collaboration with Telix exploring PSMA-PET imaging in robotic HIFU and theranostics, underscore the company's broader clinical and commercial momentum.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary considerably in strategy, holding timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum models to longer-horizon trend systems. The page is designed to help traders and investors evaluate automated, data-driven tools that complement traditional research. Exploring the section can provide additional perspective on how algorithmic strategies are currently positioned across the market.

2026 Outlook and What Investors Should Watch

The primary near-term event is the third-quarter 2026 earnings release scheduled for November 5, 2026, which will provide a read on HIFU system placements, procedure volumes, gross margin, and whether full-year guidance of $50 million to $54 million remains intact. Investors will also monitor progress toward the company's stated 40% revenue CAGR target through 2028, expansion of its U.S. installed base, and development of newer indications such as BPH and endometriosis. Key risks include continued operating losses, balance-sheet and funding considerations, the pace of reimbursement adoption, and competitive dynamics in the broader prostate cancer treatment market. Analyst expectations remain focused on whether commercial execution can translate rising procedure demand into improved profitability over time.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for FOCL with price predictions
Nov 18, 2026

FOCL sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In 70 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for FOCL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

FOCL moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FOCL's RSI Oscillator exited the oversold zone, 28 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

FOCL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-48.608) is normal, around the industry mean (14.423). P/E Ratio (-3.192) is within average values for comparable stocks, (11.188). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. FOCL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are McKesson Corp (NYSE:MCK).

Industry description

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

Market Cap

The average market capitalization across the Medical Distributors Industry is 23.75B. The market cap for tickers in the group ranges from 44.8K to 123.68B. MCK holds the highest valuation in this group at 123.68B. The lowest valued company is COCM at 44.8K.

High and low price notable news

The average weekly price growth across all stocks in the Medical Distributors Industry was -13%. For the same Industry, the average monthly price growth was -25%, and the average quarterly price growth was -28%. MCK experienced the highest price growth at 0%, while ACH experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Medical Distributors Industry was 60%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 48
Price Growth Rating: 61
SMR Rating: 88
Profit Risk Rating: 73
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of minimally invasive medical devices for urological diseases

Industry MedicalDistributors

Industry
Biotechnology
Address
Parc d'Activites La Poudrette-Lamartine
Phone
+33 472153150
Employees
289
Web
http://www.focalone.com
FocalTherics (FOCL) Stock Analysis: Robotic HIFU Expansion Sets the Stage for Q3 Results